Clinical effectiveness of combined topical remedy «Triderm» in treatment of chronic eczema

Abstract

Listen

Translate article

Objective — evaluation of the effectiveness, safety and tolerability of the local remedy «Triderm» in the treatment of patients with chronic eczema (ChE). Materials and methods. 30 patients with ChE aged from 25 to 47 years were examined. Among the patients, the diagnosis of true eczema (TE) complicated by secondary infection was established in 37.7%, microbial eczema (ME) — in 63.3 % of cases. A mild degree of severity of ChrE was established in 18 (60.0 %) patients (in 6 with TE, 12 with ME), moderate — in 12 (40.0 %) patients (in 5 with TE, in 7 with ME). Patients used the topical combined glucocorticosteroid «Triderm» twice a day for 14 days. The clinical effectiveness of the local drug was evaluated on the 7th and 14th days of treatment and on the 28th day after the start of therapy according to the dynamics of EASI (Eczema Area and Severity Index), visual analog scale (VAS) of itching, numerical rating scale (NRS) and Dermatological Index of Quality of Life (DIQL). Results and discussion. As a result of the use of «Triderm», positive changes in clinical manifestations were achieved in all patients with ChE — clinical remission (decrease in EASI by more than 75 % from the initial state) was determined in 70 % of patients; significant clinical improvement (decrease in EASI by 50—75 %) and improvement of 30 % (decrease of EASI by 25—50 %), disappearance or significant weakening of itching (decrease in intensity of itching by 4.3 times according to VAS and 3.9 times according to NRS), significant improvement of quality of life (absence of disease impact on life in 76.7 % of patients). Faster improvement and regression of dermatosis, recovery of other dermatological indicators occurred with a mild degree, compared to a medium-severe one. Conclusions. The use of the local combined drug «Triderm» which has anti-inflammatory, antibacterial and antimycotic effects, determines the high efficiency of chronic eczema therapy at various stages of the inflammatory process. The clinical effectiveness of «Triderm» allows it to be recommended for the topical therapy of dermatoses in the pathogenesis of which inflammation, bacterial and fungal flora are important (complicated true and microbial eczema, atopic dermatitis, etc.). The use of «Triderm» cream/ointment allows increasing the compliance, reducing the risk of developing unwanted reactions and interactions between active substances. The good tolerability of the drug and the absence of side effects indicate a favorable safety profile of the studied drug.